Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 6/20 | 0.73 |
| ▸ | MAPT | P10636 | 4/20 | 0.73 |
| ▸ | RAB9A | P51151 | 3/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.73 |
| ▸ | TSHR | P16473 | 1/20 | 0.73 |
| ▸ | ATM | Q13315 | 1/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.73 |
| ▸ | APP | P05067 | 1/20 | 0.63 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.55 |
| ▸ | RELA | Q04206 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11015064 | 0.87 | TP53 (0.73) | TP53MAPTRAB9ALMNASMN1; SMN2 | |
| SCHEMBL11012567 | 0.85 | TP53 (0.57) | TP53MAPTRAB9ALMNASMN1; SMN2 | |
| SCHEMBL13650900 | 0.85 | LMNA (0.55) | TP53MAPTRAB9ALMNASMN1; SMN2 | |
| SCHEMBL11015014 | 0.84 | TP53 (1.00) | TP53MAPTRAB9ALMNASMN1; SMN2 | |
| SCHEMBL11015020 | 0.84 | TP53 (0.81) | TP53MAPTRAB9ALMNASMN1; SMN2 | |
| SCHEMBL84416 | 0.84 | RAB9A (0.64) | TP53MAPTRAB9ALMNASMN1; SMN2 | |
| SCHEMBL24106015 | 0.83 | TP53 (0.55) | TP53MAPTRAB9ALMNASMN1; SMN2 | |
| SCHEMBL11351985 | 0.83 | MAPT (0.61) | TP53MAPTRAB9ALMNASMN1; SMN2 | |
| SCHEMBL13198300 | 0.82 | TP53 (0.70) | TP53MAPTRAB9ALMNASMN1; SMN2 | |
| SCHEMBL10803793 | 0.82 | TP53 (0.60) | TP53MAPTRAB9ALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11559518-B2 | Endoplasmic reticulum stress regulator comprising benzothiazoimidazolyl compound | ER STRESS RESEARCH INSTITUTE, INC. (JP) | 2023-01-24 | — | — | US | disclosed |
| US-20210386715-A1 | ENDOPLASMIC RETICULUM STRESS REGULATOR COMPRISING BENZOTHIAZOIMIDAZOLYL COMPOUND | ER STRESS RESEARCH INSTITUTE, INC. (JP) | 2021-12-16 | — | — | US | disclosed |
| EP-0524055-A1 | Imidazo(2,1-b)benzothiazole-3-acetamide derivatives, process for their preparation and their therapeutical use | SYNTHELABO (FR) | 1993-01-20 | — | — | EP | disclosed |
| US-4497817-A | ANTIALLERGENS-IMMUNOSUPPRESSIVE AGENTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1985-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11559518-B2 | Endoplasmic reticulum stress regulator comprising benzothiazoimidazolyl compound | HSPA5, DNAJC10, ERP44 | TP53 1281/4885MAPT 3116/4885RAB9A 1684/4885 |
| US-20210386715-A1 | ENDOPLASMIC RETICULUM STRESS REGULATOR COMPRISING BENZOTHIAZOIMIDAZOLYL COMPOUND | DNAJC10, HSPA5, ERP44 | TP53 1668/4885MAPT 3271/4885RAB9A 2027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.